Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group A (n = 60): Low-calorie diet and physical activity design based on the Adult Overweight and Obesity Control Guide (published by the US National Heart, Lung, and Bloo
Sponsors
Vice-chancellor for research Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Desire to participate in studying and signing consent Diagnosis of non-alcoholic fatty liver according to criteria of the American Gastroenterology Association (33): Evidence of hepatic steatosis in liver ultrasound (grade 1 to 3 fatty liver), ALT and AST increased than normal (AST> 38 and ALT> 40 for men and more than 31 and 33 for women), the absence of conditions or diseases secondary to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), Known autoimmune disease, history of hepatotoxic drugs (methotrexate, aminodarone, tamoxifen, nifedipine, corticosteroids, valproate, and medications) The virus) and non-use of anticoagulant drugs such as aspirin. Not getting other diseases and chronic and acute liver disorders (hepatitis B, C, etc.), cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, kidney, pulmonary and inflammatory diseases (rheumatism) BMI in the range of 40-25 Kg / m2 The age range is 20 to 65 years No use of any nutritional supplements in the past two months No use of weight-effective drugs over the past two months Not having a weight loss diet (a decrease of more than 10% of the weight) over the past three months Do not use drugs and cigarettes No pregnancy or lactation
Exclusion criteria
Exclusion criteria: Secondary conditions that lead to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), and known autoimmune diseaseOther chronic and acute liver diseases and disorders such as hepatitis, cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, renal, pulmonary and inflammatory diseases (rheumatism)History of taking hepatotoxic drugs (methotrexate, amiodarone, tamoxifen, nifedipine, corticosteroids, valproate and antiviral drugs) as well as anticoagulants such as aspirin Use of any nutritional supplement in the past two months Use of weight-loss drugs over the past two months Having a severe weight loss diet (more than 10% weight loss) over the past three months smoking Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALT. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;AST. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;ALP. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;GGT. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;TG. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzyme colorimetric method.;TC. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzyme colorimetric method.;HDL-C. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzyme colorimetric method.;FBS. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzymatic calorie meter method.;Insulin. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: ELISA.;LDL-C. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: calculation.;HOMA-Insulin resistance. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: calculation.;HOMA- ß%. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: calculation.;QUICKI. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: calculation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Scales.;Height. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Meter.;Waist. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Meter.;BMI. Timepoint: Before intervention and 8 months after intervention. Method of measurement: calculation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Nahid Aryaeian
Iran University of Medical Sciences
Outcome results
None listed